FDA Licenses Sanofi Pasteur's Pediatric Combination Vaccine, Pentacel
More News related to SNY
- Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
- Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
- (OVIT.OB) OncoVista Issued $16 Price Target From Status Equity Research
- Status Equity Research Initiates Coverage of OncoVista Innovative Therapies, Inc. (OVIT.OB) -- Long Term Target Price $16.00
- National Transitions of Care Coalition Hosted Information Exchange on the Issue of Transitions of Care
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (NYSE: SNY), announced the U.S. Food and Drug Administration (FDA) has licensed Pentacel, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine. Pentacel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to Haemophilus influenzae type b (Hib). Pentacel(R) vaccine is approved for use in infants and children 6 weeks through 4 years of age (prior to fifth birthday).
Pentacel vaccine is the first and only four-dose diphtheria, tetanus, and acellular pertussis (DTaP)-based combination vaccine for use in infants and young children in the U.S. that includes both poliovirus and Hib antigens.
Sanofi-Aventis is a pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products.
Related Categories
FDAStocks Mentioned
-0.05Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
